Pfizer will be conducting a clinical trial for its Respiratory Syncytial Virus (RSV) treatment PF-07923568 (sisunatovir) on infants and children in Korea.

On the 7th, the Ministry of Food and Drug Safety approved Pfizer Korea's ‘Interventional, phase 1B, randomized, double-blinded, sponsor-open, placebo-controlled, multicenter, dose-finding study to evaluate the safety, tolerability, and pharmacokinetics of sisunatovir in pediatric participants up to 60 months of age with respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI).’

The study will be conducted at Seoul National University Bundang Hospital, Severance Hospital, Seoul National University Hospital, and Korea